Published in Cancer Lett on February 06, 2009
Quantitative interactome analysis reveals a chemoresistant edgotype. Nat Commun (2015) 0.96
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia (2011) 0.81
Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. PLoS One (2012) 0.79
Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition. J Exp Clin Cancer Res (2013) 0.77
Clinical scenario 1 is associated with winter onset of acute heart failure. Circ J (2014) 1.97
Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J (2012) 1.58
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des (2006) 1.55
Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia. Circ J (2015) 1.55
Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J (2012) 1.53
Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One (2011) 1.52
Endovascular aortic repair increases vascular stiffness and alters cardiac structure and function. Circ J (2013) 1.49
Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun (2003) 1.48
Effect of therapeutic moderate hypothermia on multi-drug resistance protein 1-mediated transepithelial transport of drugs. Neurol Med Chir (Tokyo) (2006) 1.47
Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen. Int J Urol (2011) 1.45
Electrophysiological properties of prion-positive cardiac progenitors derived from murine embryonic stem cells. Circ J (2012) 1.40
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther (2002) 1.30
Comparative pulmonary toxicity study of nano-TiO(2) particles of different sizes and agglomerations in rats: different short- and long-term post-instillation results. Toxicology (2009) 1.25
Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation (2004) 1.24
Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull (2002) 1.23
Protein adsorption of ultrafine metal oxide and its influence on cytotoxicity toward cultured cells. Chem Res Toxicol (2009) 1.23
Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res (2006) 1.22
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res (2011) 1.15
Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci (2012) 1.11
Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol (2007) 1.10
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res (2006) 1.08
Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol Pharmacol (2002) 1.07
Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet (2006) 1.07
Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev (2008) 1.06
Pulmonary toxicity of well-dispersed multi-wall carbon nanotubes following inhalation and intratracheal instillation. Nanotoxicology (2011) 1.06
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci (2011) 1.05
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol (2006) 1.05
Development and evaluation of an aerosol generation and supplying system for inhalation experiments of manufactured nanoparticles. Environ Sci Technol (2009) 1.04
Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol (2004) 1.03
Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene (2003) 1.03
Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull (2012) 1.02
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun (2004) 1.01
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet (2006) 1.00
Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull (2003) 0.99
N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull (2002) 0.98
AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension (2004) 0.98
Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit (2005) 0.98
Inflammogenic effect of well-characterized fullerenes in inhalation and intratracheal instillation studies. Part Fibre Toxicol (2010) 0.98
Expression of cytokine-induced neutrophil chemoattractant in rat lungs by intratracheal instillation of nickel oxide nanoparticles. Inhal Toxicol (2009) 0.98
Noninvasive assessment of wall distensibility with the evaluation of diastolic epicardial movement. J Card Fail (2009) 0.98
Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos (2002) 0.97
20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol (2013) 0.96
Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull (2002) 0.96
The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. Biol Pharm Bull (2009) 0.95
Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol (2005) 0.95
A determination method of pristine multiwall carbon nanotubes in rat lungs after intratracheal instillation exposure by combustive oxidation-nondispersive infrared analysis. Talanta (2011) 0.95
Quantitative structure--activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry (2007) 0.94
Gene expression profiles in rat lung after inhalation exposure to C60 fullerene particles. Toxicology (2009) 0.94
Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol (2007) 0.93
Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol (2004) 0.93
TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res (2010) 0.93
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol (2003) 0.93
Ultrafine NiO particles induce cytotoxicity in vitro by cellular uptake and subsequent Ni(II) release. Chem Res Toxicol (2009) 0.92
Focal hepatic steatosis surrounding a metastatic insulinoma. Pathol Int (2008) 0.91
Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics (2008) 0.91
The effect of placebo administration on the first-night effect in healthy young volunteers. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.91
Pulmonary toxicity of well-dispersed single-wall carbon nanotubes after inhalation. Nanotoxicology (2011) 0.91
Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci (2009) 0.90
Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1. J Biol Chem (2012) 0.90
Chromium(III) oxide nanoparticles induced remarkable oxidative stress and apoptosis on culture cells. Environ Toxicol (2011) 0.90
Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res (2002) 0.90
L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens (2012) 0.90
Expression of inflammation-related cytokines following intratracheal instillation of nickel oxide nanoparticles. Nanotoxicology (2010) 0.90
An operative case of hepatic pseudolymphoma difficult to differentiate from primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. World J Surg Oncol (2011) 0.89
Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent. Radiology (2003) 0.89
Biopersistence of inhaled MWCNT in rat lungs in a 4-week well-characterized exposure. Inhal Toxicol (2011) 0.89
Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull (2005) 0.89
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci (2012) 0.89
Matrilysin (matrix metalloprotease-7) cleaves membrane-bound annexin II and enhances binding of tissue-type plasminogen activator to cancer cell surfaces. FEBS J (2008) 0.88
Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J (2011) 0.88
Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res (2003) 0.88
Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci (2011) 0.88
Electroporation-mediated gene transfer system applied to cultured CNS neurons. Neuroreport (2004) 0.88
Studies on interactions between traditional herbal and western medicines. V. effects of Sho-saiko-to (Xiao-Cai-hu-Tang) on the pharmacokinetics of carbamazepine in rats. Biol Pharm Bull (2002) 0.88
Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol (2008) 0.88
Primary hepatic benign schwannoma. World J Gastrointest Surg (2012) 0.88
Effects of low-dose human atrial natriuretic peptide for preventing post-operative cardiopulmonary complications in elderly patients undergoing pulmonary resection for lung cancer. Eur J Cardiothorac Surg (2012) 0.87
Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull (2003) 0.87
Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. J Mol Biol (2011) 0.87
Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J (2012) 0.87
Group IB secretory phospholipase A2 induces neuronal cell death via apoptosis. J Neurochem (2002) 0.87
Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res (2011) 0.87
Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. Eur J Pharm Sci (2009) 0.87
Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery. Eur J Cardiothorac Surg (2012) 0.87
In vitro evaluation of cellular responses induced by stable fullerene C60 medium dispersion. J Biochem (2010) 0.86
Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail (2011) 0.86
Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells. Mol Med Rep (2011) 0.86